

Vermont Vaccine Purchasing Program Assessment Calculation Worksheet

Column →	A		B	C		D	E
	CHILDREN			ADULTS			
Line ↓	Prior July 2020	July 2021-June 2022		Prior July 2020	July 2021-June 2022		Comments
A. Preliminary Vaccine Cost Estimates							
01.	14,603,489	15,541,634		4,200,397	6,046,539		Estimated costs of vaccines (sheets e & f)
02.	73,017	77,708	0.50%	21,002	30,233	0.50%	Provision for vaccine utilization increase
03.	0	0	0.00%	147,749	212,687	3.50%	¹ Provision for vaccine cost increase (% is annual)
04.	14,676,506	15,619,342		4,369,148	6,289,458		Est. vaccines costs(w/utilization & price adjustments.)
05.	-7,739,849	-8,547,899		-338,378	-338,378		Estimated VFC Award & 317 federal grant
06.	0	0		0	0		Other
07.	6,936,657	7,071,443		4,030,770	5,951,080		Total estimated VVPP vaccine costs
B. Assessable Covered Lives Estimates							
08.	59,795	59,110		337,444	338,380		Assessable covered lives (sheet c)
09.	0	0	0.00%	0	0	0.00%	Leakage (unknown insurer, out of reach entity, etc.)
10.	59,795	59,110		337,444	338,380		Assessable lives actually paying
C. Financial Carry Forwards							
11.	671,357	-1,075,986		390,523	-625,237		Vaccine fund carryforward (sheet d.)
12.	0	0	0.0	0	0	0.0	Amt. retained for liquidity reserve /reserve months
13.	671,357	-1,075,986		390,523	-625,237		Carryforward to reduce (add to) current assessment
D. Operational and Other Fixed Costs							
14.	256,656	261,643	3.70%	149,138	220,190	3.70%	VDH operational cost
15.	120,771	109,296		70,171	88,337		Administrative fees - KidsVax (from sheet b.)
16.	719	733	0.01%	418	617	0.01%	Bad debt allowance
17.	378,146	371,672		219,727	309,144		Sub-total anticipated operating costs
18.	0	0	0.00%	0	0	0.00%	Working capital reserve build-up
19.	0	0	0.00%	0	0	0.00%	Risk reserves
20.	\$ 378,146	\$ 371,672		\$ 219,727	\$ 309,144		Total fixed costs
E. Assessment Calculation							
21.	\$ 7,314,803	\$ 7,443,115		\$ 4,250,496	\$ 6,260,224		Total assessment funds needed (Line 7 + Line 20)
22.	\$ (671,357)	\$ 1,075,986		\$ (390,523)	\$ 625,237		Plus carry forward credit
23.	\$ 6,643,446	\$ 8,519,101		\$ 3,859,973	\$ 6,885,461		Net assessment funds needed
F. Per Assessable Covered Life Assessment							
24.	\$111.12	\$144.24		\$11.52	\$20.40		Annual assessment per covered life
25.	\$9.26	\$12.02		\$0.96	\$1.70		Monthly assessment per covered life calculated
26.	\$9.26	\$12.02		\$0.96	\$1.70		Monthly assessment per covered life recommended
G. Unexpended Assessments							
27.	719	733		418	617		² Unexpended assessments
H. Various Performance Metrics							
28.	1.74%	1.55%		1.74%	1.48%		Administrative fees - KidsVax as % of vaccine costs
29.	5.44%	5.25%		5.44%	5.18%		VDH operational cost & KV admin. fee as a % of vaccines
30.	0.00%	29.81%		0.00%	77.08%		% year to year change in assessment rate
31.	\$ 10.19	\$10.49		\$1.05	\$1.54		³ "Normalized" assessment rate (w/o lines 11, & 18)
32.	10.1%	-12.7%		9.3%	-9.3%		% Change from monthly assessment rate
33.	\$ 10.60	\$10.91		\$1.09	\$1.60		⁴ Preliminary Assessment projection
34.	14.5%	-9.2%		13.7%	-5.7%		Preliminary Assessment increase
I. Vaccine Cost per Covered Life determination							
35.	\$	119.64		\$	17.64		Annual vaccine cost calculated
36.	\$ 9.67	\$ 9.97		\$ 1.00	\$ 1.47		Monthly vaccine cost calculated

Notes:

- ¹ The CDC contract prices change dates are 4/1 for childhood vaccines and 7/1 for adult vaccines.
The child price increase is 0 on Line 3 because VDH anticipates purchasing vaccines administered in April-June 2022 in March 2022, at April 2021 prices. All childhood vaccine cost projections are based on April 2020 CDC pricing.
The line 3 provision for cost increases is applied for 12 months for adult vaccines in order to estimate July 2021 CDC prices.
- ² Carryforward cash amounts, if any, will be used for a working capital reserve if needed, and then applied to reduce future assessments unless otherwise directed by VDH.
- ³ This rate assumes that the working capital reserve is adequate and so included no reserves and also no carry forward.
- ⁴ Preliminary projection: This is the normalized assessment rate and one additional year of inflation and utilization changes.

Vermont Vaccine Purchasing Program Budget Estimates and Allocations

Column →	A	B	C	D	E	F	G	H
Line ↓	CHILDREN					ADULT		
	Prior Year	Unallocated ¹	Specific	Allocated ¹	Total	Specific	Allocated ¹	Total
01. Administrative Fees (KidsVax®)								
02. Annual Base Fee	\$190,950	\$197,633 ²		\$109,296	\$109,296		\$88,337	\$88,337
03. Expense Allowance (travel)		\$0 ⁵		\$0	\$0		\$0	\$0
04. Other	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>
05. Subtotal	\$190,950	\$197,633	\$0	\$109,296	\$109,296	\$0	\$88,337	\$88,337
General Expenses								
06. Bank Fees & Service Charges	\$0			\$0	\$0		\$0	\$0
07. Auditing Fees				\$0	\$0		\$0	\$0
08. Legal Fees				\$0	\$0		\$0	\$0
09. VVPP Miscellaneous Expenses				\$0	\$0		\$0	\$0
10. Office Expense				\$0	\$0		\$0	\$0
11. Telephone Expense				\$0	\$0		\$0	\$0
12. Postage and Shipping Expense				\$0	\$0		\$0	\$0
13. Significant Website Enhancement				\$0	\$0		\$0	\$0
14. Public Information Expense (other than web site)				\$0	\$0		\$0	\$0
15. Insurance Expense (D&O)				\$0	\$0		\$0	\$0
16. Printing Expense				\$0	\$0		\$0	\$0
17. Publications				\$0	\$0		\$0	\$0
18. Travel Expense				\$0	\$0		\$0	\$0
19. Meeting Expense		<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>
20. Subtotal	\$0	\$0 ⁵	\$0	\$0	\$0	\$0	\$0	\$0
Special Projects								
21.				\$0	\$0		\$0	\$0
22.				\$0	\$0		\$0	\$0
23.		<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>
24. Subtotal		\$0	\$0	\$0	\$0	\$0	\$0	\$0
25. Total Expenses	<u>\$190,950</u>	<u>\$197,633</u>	<u>\$0</u>	<u>\$109,296</u>	<u>\$109,296</u>	<u>\$0</u>	<u>\$88,337</u>	<u>\$88,337</u>
26. Budgeted for Bad Debt								

NOTES:

¹ "Unallocated" in this spreadsheet means that the specific item is not specific to either child or adult vaccines. If no other rule is given, allocation will be based upon the ratio of the child & adult total vaccine costs, plus VDH administrative fees (tab a. line 9), plus any carry forward credit or debit (tab a. line 15), respectively, to the total. That computation is as follows:

total child: 8,409,072 total adult: 6,796,507 55.30% is the child % of total

² Comprehensive fee for July 2020 through June 2021.

³ No plans for implementation of lockbox.

⁴ Actual costs, if any. Presently expected to be zero.

⁵ Bundled in KidsVax comprehensive fee for normal amounts.

⁶ To be set as part of the assessment work.

Estimated Covered Lives for Assessment Calculation

Covered lives reported to KidsVax for the historical quarter:

Column → Line ↓	A	B	C		D	E	F		G	H		I	J		K
	Assessment Quarter	Membership Period	Quarter			Kids	Adults	Monthly Average	Total	Kids	Adults	Variance	Monthly Average (using 12 months)		
			Kids	Adults		Kids	Adults			Kids	Adults		Kids	Adults	
01.	Q4	10/2016-12/2016	175,240	1,034,868		58,413	344,956		403,369	-0.2%	-1.9%		58,687	356,268	
02.	Q1	1/2017-3/2017	175,428	1,038,732		58,476	346,244		404,720	0.1%	0.4%		58,512	351,454	
03.	Q2	4/2017-6/2017	174,315	1,036,591		58,105	345,530		403,635	-0.6%	-0.2%		58,377	347,132	
04.	Q3	7/2017-9/2017	173,468	1,024,991		57,823	341,664		399,486	-0.5%	-1.1%		58,204	344,599	
05.	Q4	10/2017-12/2017	174,257	1,018,974		58,086	339,658		397,744	0.5%	-0.6%		58,122	343,274	
06.	Q1	1/2018-3/2018	175,221	1,036,184		58,407	345,395		403,802	0.6%	1.7%		58,105	343,062	
07.	Q2	4/2018-6/2018	179,314	1,037,108		59,771	345,703		405,474	2.3%	0.1%		58,522	343,105	
08.	Q3	7/2018-9/2018	177,639	1,027,998		59,213	342,666		401,879	-0.9%	-0.9%		58,869	343,355	
09.	Q4	10/2018-12/2018	179,885	1,018,717		59,962	339,572		399,534	2.5%	-1.9%		59,338	343,334	
10.	Q1	1/2019-3/2019	178,304	1,024,917		59,435	341,639		401,074	-0.9%	0.6%		59,595	342,395	
11.	Q2	4/2019-6/2019	179,777	1,016,235		59,926	338,745		398,671	0.8%	-0.8%		59,634	340,656	
12.	Q3	7/2019-9/2019	179,153	1,005,968		59,718	335,323		395,040	-0.3%	-1.0%		59,760	338,820	
13.	Q4	10/2019-12/2019	180,310	1,002,208		60,103	334,069		394,173	2.9%	-3.3%		59,795	337,444	
14.	Q1	1/2020-3/2020	180,326	1,006,742		60,109	335,581		395,689	0.6%	-2.9%		59,964	335,929	
15.	Q2	4/2020-6/2020	178,807	1,014,460		59,602	338,153		397,756	0.7%	-1.3%		59,883	335,782	
16.	Q3	7/2020-9/2020	176,618	1,016,410		58,873	338,803		397,676	-1.8%	-0.2%		59,672	336,652	
17.	Q4	10/2020-12/2020	173,572	1,022,951		57,857	340,984		398,841	-2.7%	-0.2%		59,110	338,380	
18.		Best Current Estimate (average of the four most recent quarters)											59,110	338,380	

Prior Year's Financial Recap

Column → Line ↓	A	B	C
Revenues			
01.	Carryforward from prior year (available cash on hand at 4/1/20)	-\$1,530,575	
02.	Prior Year Reconciliation: VVPP assessment collections 4/1/20-6/30/20	\$508,756	
03.	VVPP assessment collections over reconciliation period 7/1/20-3/31/21	\$7,715,949	
04.	Estimated VVPP assessment collections 4/1/21-6/30/21	\$2,571,983	
05.	Total Revenues		\$9,266,113
Expenditures / Allowances			
06.	Prior Year Reconciliation: vaccine purchase 7/1/19-6/30/20	\$1,313,948	
07.	Total vaccine purchases 7/1/20-3/31/21	\$9,142,909	
08.	Estimated vaccine purchase 4/1/21-6/30/21	\$225,000	
09.	Prior Year Reconciliation: KidsVax 4/1/20-6/30/20	-\$8,590	
10.	KidsVax 7/1/20-3/31/21	\$172,867	
11.	Estimated KidsVax 4/1/21-6/30/21	\$26,673	
12.	Prior Year Reconciliation: VDH operational cost 1/1/20-6/30/20	-\$12,250	
13.	VDH operational cost 7/1/20-3/31/21	\$70,991	
14.	Estimated VDH operational cost 4/1/21-6/30/21	\$35,788	
15.	Total Expenditures/Allowances		<u>-\$10,967,335</u>
16.	Vaccine Fund Carryforward ¹ (applied to increase this year's assessment)		-\$1,701,223

Notes: ¹ Excess of expenditures over revenue.

VT DOH Pediatric Vaccine Purchase Estimates
Federal Fiscal Year

Column →
Line ↓

	A	B	C	D	E	F	G	H	
	Vaccine	Brand Name	VVPP Cost Per Dose ¹	FFY22 estimated doses	FFY22 estimated cost	FFY21 total estimated doses	FFY21 actual doses distributed 10/1/20-3/31/21	Actual/Estimate as a %	
01.	DTaP	Daptacel	\$19.202	800	\$ 15,362	800	200	25%	
02.		Infanrix	\$19.840	6,100	\$ 121,024	5,000	2,530	51%	
03.	DTaP-HepB-IPV	Pediarix	\$62.492	8,000	\$ 499,936	11,000	5,140	47%	
04.	DTaP-IPV/Hib	Pentacel	\$63.384	5,000	\$ 316,920	8,500	3,775	44%	
05.	DTaP-IPV-Hib-HepB	Vaxelis*	\$80.000	5,220	\$ 417,600	n/a	n/a	n/a	
06.	DTaP-IPV	Kinrix	\$43.643	4,000	\$ 174,572	4,000	2,340	59%	
07.		Quadracel	\$43.352	2,200	\$ 95,374	2,200	850	39%	
08.	Hib	ActHIB	\$10.020	12,000	\$ 120,240	15,000	6,910	46%	
09.		PedvaxHIB	\$13.790	4,000	\$ 55,160	150	60	40%	
10.		Hiberix	\$9.621	0	\$ -	-	-	0%	
11.	HepA	Vaqta	\$21.400	0	\$ -	-	-	0%	
12.		Havrix	\$21.724	18,000	\$ 391,032	18,000	7,420	41%	
13.	HepB	Recombivax	\$13.000	5,000	\$ 65,000	5,000	3,440	69%	
14.		Engerix B	\$15.673	2,000	\$ 31,346	4,000	40	1%	
15.	HPV	Gardasil	\$196.320	16,000	\$ 3,141,120	16,000	6,270	39%	
16.	IPV	IPOLE	\$14.060	2,500	\$ 35,150	2,200	1,380	63%	
17.	Influenza	Fluzone - Quad	\$13.755	12,000	\$ 165,060	24,000	24,000	100%	
18.			\$13.755	0	\$ -	-	300	n/a	
19.			\$13.755	12,000	\$ 165,060	24,000	24,260	101%	
20.		FluMist	\$18.880	1,500	\$ 28,320	3,000	1,030	34%	
21.		Fluarix	\$14.250	18,000	\$ 256,500	7,000	10,000	143%	
22.		FluLaval	\$14.250	24,000	\$ 342,000	7,000	7,000	100%	
23.		Afluria	\$14.010	0	\$ -	-	180	n/a	
24.		Afluria	\$14.010	0	\$ -	-	1,090	n/a	
25.		Flucelvax	\$17.870	0	\$ -	-	800	n/a	
26.	MMR	MMR II	\$22.110	7,500	\$ 165,825	7,500	2,880	38%	
27.	MMRV	ProQuad	\$144.625	7,500	\$ 1,084,688	7,500	3,150	42%	
28.	MCV4 / MenACWY	Menactra	\$100.050	12,500	\$ 1,250,625	12,500	5,725	46%	
29.		Menveo	\$99.582	100	\$ 9,958	100	25	25%	
30.	MENB	Trumenba	\$119.930	0	\$ -	-	-	0%	
31.		Bexsero	\$128.604	3,000	\$ 385,812	3,000	831	28%	
32.	PCV13	Prevnar 13	\$150.830	25,000	\$ 3,770,750	24,000	10,510	44%	
33.	PPSV23	Pneumovax 23	\$62.080	100	\$ 6,208	200	10	5%	
34.	RV	RotaTeq	\$74.730	8,000	\$ 597,840	7,500	3,590	48%	
35.		Rotarix	\$99.443	6,000	\$ 596,658	5,500	2,390	43%	
36.	Td	TDVAX	\$16.546	800	\$ 13,237	800	238	30%	
37.	Tdap	Boostrix	\$34.067	7,500	\$ 255,503	7,200	4,570	63%	
38.		Adacel	\$33.160	3,000	\$ 99,480	2,500	1,280	51%	
39.	VAR	Varivax	\$115.770	7,500	\$ 868,275	7,500	2,930	39%	
40.					246,820	\$ 15,541,634	242,650	147,144	

41. ¹ CDC pediatric vaccine contract prices as of 4/1/21

42. 20-21 flu season distribution 9/1/20-3/31/21

43. *Vaxelis cost is an estimate, only.

44.

45. Estimated VFC portion 55% \$ 8,547,899

VT DOH Adult Vaccine Purchase Estimates
Federal Fiscal Year

Column →
Line ↓

	A	B	C	D	E	F	G	H
	Vaccine	Brand Name	VVPP Cost Per Dose ¹	FFY22 estimated doses	FFY22 estimated cost	FFY21 total estimated doses	FFY21 actual doses distributed 10/1/20-3/31/21	Actual/Estimate as a %
01.	HepA	Vaqta	\$32.860	1,700	\$55,862	1700	1500	88%
02.		Havrix	\$32.860	3,500	\$115,010	3900	640	16%
03.	HepB	Engerix B	\$25.810	2,500	\$64,525	2500	790	32%
04.		HepLisav-B	\$73.050	2,000	\$146,100	2500	325	13%
05.	HepA-HepB	Twinrix	\$62.035	1,500	\$93,053	1500	570	38%
06.	HPV	Gardasil	\$140.587	4,500	\$632,642	4500	1780	40%
07.	Influenza	Fluarix	\$13.040	16,000	\$208,640	22500	26470	118%
08.		FluLaval	\$13.040	27,500	\$358,600	22500	24470	109%
09.		Afluria	\$12.480	0	\$0	0	170	n/a
10.		Fluzone	\$12.808	0	\$0	0	1200	n/a
11.		Fluzone	\$14.223	4,000	\$56,892	0	1030	n/a
12.		Flucelvax	\$14.440	0	\$0	0	1970	n/a
13.		Flucelvax	\$15.450	0	\$0	0	3180	n/a
14.	FluMist	\$18.190	0	\$0	0	210	n/a	
15.	MMR	MMR II	\$48.861	500	\$24,431	500	240	48%
16.	MCV4 /	Menactra	\$75.284	1,000	\$75,284	1000	460	46%
17.	MenACWY	Menveo	\$70.118	0	\$0	0	0	n/a
18.	MENB	Trumenba	\$93.140	0	\$0	0	0	n/a
19.		Bexsero	\$106.888	550	\$58,788	550	179	33%
20.	PCV13	Prevnar 13	\$131.606	1,250	\$164,508	1500	360	24%
21.	PPSV23	Pneumovax 23	\$62.689	5,000	\$313,445	5000	2637	53%
	RZV	Shingrix	\$102.221	30,000	\$3,066,630	12000	15778	131%
	Td	TDVAX	\$16.269	7,000	\$113,883	7000	3039	43%
	Tdap	Boostrix	\$25.428	14,750	\$375,063	14750	5440	37%
		Adacel	\$26.089	4,250	\$110,878	4250	1920	45%
	VAR	Varivax	\$82.039	150	\$12,306	150	110	73%

\$6,046,539

¹ CDC adult vaccine contract purchase prices as of 4/1/21
20-21 flu season distribution 9/1/20-3/31/21

estimated 317 \$338,378